EMAIL THIS PAGE TO A FRIEND

Cytometry. Part B, Clinical cytometry

Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.


PMID 23922218

Abstract

Multiple myeloma (MM) is a malignancy of plasma cells frequently associated with immune abnormalities. Several studies have confirmed that in MM immune deregulation can be mediated by increased numbers of CD4 T regulatory (Treg) cells, and these cells were also associated with poor outcome. In this study, we aimed to study CD8 Treg cells before and after lenalidomide plus dexamethasone (len-dex) treatment in MM patients. Using flow cytometry, we enumerated and assessed suppressive function of CD8 Treg cells in 16 MM patients before and after len-dex treatment. Numbers of CD8 Treg cells (CD8+CD25hi+FoxP3+) (P < 0.01) were significantly increased in MM patients (before treatment) compared to healthy donors. However, no significant changes were observed in CD4 and CD8 T cells. A significant increase in CD8 Treg cells was observed after len-dex treatment compared to pre-treatment but no significant difference was observed in CD4 and CD8 T cells. Proliferation assay data showed that CD8 Treg cells inhibited proliferation of CD4 T cells and IFN-γ secretion in a concentration dependent manner. Suppressive activity of CD8 Treg cells did not differ significantly between healthy donors, untreated and len-dex treated MM patients. A significant abnormal level of IL-10 was observed from proliferation assays of untreated and len-dex treated MM patients compared to healthy donors (P ≤ 0.03). Using flow cytometry, we have shown that suppressive CD8 Treg cells are increased in MM patients and len-dex treatment is unable to control these suppressive CD8 Treg cells.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV41764
Anti-GNAS (AB1) antibody produced in rabbit, IgG fraction of antiserum
AV41765
Anti-GNAS (AB2) antibody produced in rabbit, IgG fraction of antiserum
AV42694
Anti-GNAS (AB3) antibody produced in rabbit, IgG fraction of antiserum
SAB2501411
Anti-GNAS antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA018122
Anti-GNAS antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2100941
Anti-GNAS antibody produced in rabbit, affinity isolated antibody
HPA027478
Anti-GNAS antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab1
HPA028386
Anti-GNAS antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab2
SAB1400841
Anti-LIPH antibody produced in mouse, IgG fraction of antiserum, buffered aqueous solution
HPA049079
Anti-LIPH antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2107647
Anti-LIPH antibody produced in rabbit, affinity isolated antibody
HPA021656
Anti-SLC10A3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2105728
Anti-SLC10A3 antibody produced in rabbit, affinity isolated antibody